Capitaline

Results 16-Feb-23

Analysis

Biocon

Exceptional items during Q3FY23 resulted in net loss of Rs 41.8 crore

For quarter ended Dec 2022, consolidated Net sales (including other operating income) of Biocon has increased 35.27% to Rs 2941.1 crore compared to quarter ended Dec 2021. Sales of Research service segment has gone up 22.53% to Rs 785.90 crore (accounting for 26.11% of total sales). Sales of Generics segment has gone up 18.14% to Rs 717.60 crore (accounting for 23.84% of total sales). Sales of segment has gone up 53.52% to Rs 1,506.60 crore (accounting for 50.05% of total sales). Inter-segment sales came down from Rs 71.60 crore to Rs 69.00 crore.

Profit before interest, tax and other unallocable items (PBIT) has jumped 2.63% to Rs 276.70 crore. PBIT of Novel Biologics segment rose 23.98% to Rs -37.40 crore (accounting for -13.52% of total PBIT). PBIT of Research service segment rose 8.96% to Rs 139.90 crore (accounting for 50.56% of total PBIT). PBIT of Generics segment rose 8.26% to Rs 72.10 crore (accounting for 26.06% of total PBIT). PBIT of segment fell 17.53% to Rs 102.10 crore (accounting for 36.90% of total PBIT).

PBIT margin of Research service segment fell from 20.02% to 17.80%. PBIT margin of Generics segment fell from 10.96% to 10.05%. PBIT margin of segment fell from 12.61% to 6.78%. Overall PBIT margin fell from 12.00% to 9.19%.

Operating profit margin has declined from 22.45% to 21.91%, leading to 31.97% rise in operating profit to Rs 644.30 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 33.77% to 34.94%. Purchase of finished goods cost fell from 1.30% to 1.22%. Employee cost decreased from 22.00% to 18.19%. Other expenses rose from 21.24% to 24.68%. Preoperation capitalised expenses fell from 6.00% to 3.68%.

Other income rose 62.73% to Rs 78.6 crore. PBIDT rose 34.74% to Rs 722.9 crore. Provision for interest rose 718.37% to Rs 120.3 crore.

PBDT rose 15.48% to Rs 602.6 crore. Provision for depreciation rose 46.38% to Rs 301.1 crore.

Profit before tax down 4.62% to Rs 301.50 crore. Share of profit/loss was 17.80% lower at Rs -55.6 crore. Extraordinary items stood at Rs -271.4 crore compared to nil in Q3 FY22. Provision for tax was credit of Rs 4.8 crore, compared to debit of Rs 49.3 crore. Effective tax rate was 18.82% compared to 18.33%.

Minority interest decreased 35.08% to Rs 21.10 crore. Net loss attributable to owners of the company was Rs 41.8 crore compared to profit of Rs 187.1 crore.

Promoters’ stake was 60.64% as of 31 December 2022 ,compared to 60.64% as of 31 December 2021 .

For year-to-date (YTD) results analysis.

Net sales (including other operating income) of Biocon has increased 28.14% to Rs 7400.3 crore. Sales of Research service segment has gone up 19.09% to Rs 2,198.50 crore (accounting for 28.93% of total sales). Sales of Generics segment has gone up 18.25% to Rs 1,920.10 crore (accounting for 25.27% of total sales). Sales of Biosimilars segment has gone up 40.23% to Rs 3,480.60 crore (accounting for 45.80% of total sales). Inter-segment sales came down from Rs 215.30 crore to Rs 198.90 crore.

Profit before interest, tax and other unallocable items (PBIT) has jumped 3.15% to Rs 733.90 crore. PBIT of Novel Biologics segment rose 59.08% to Rs -69.20 crore (accounting for -9.43% of total PBIT). PBIT of Research service segment rose 7.98% to Rs 362.80 crore (accounting for 49.43% of total PBIT). PBIT of Generics segment rose 30.13% to Rs 189.60 crore (accounting for 25.83% of total PBIT). PBIT of Biosimilars segment fell 37.15% to Rs 250.70 crore (accounting for 34.16% of total PBIT).

PBIT margin of Research service segment fell from 18.20% to 16.50%. PBIT margin of Generics segment rose from 8.97% to 9.87%. PBIT margin of Biosimilars segment fell from 16.07% to 7.20%. Overall PBIT margin fell from 11.88% to 9.66%.

Operating profit margin has declined from 23.87% to 20.46%, leading to 9.87% rise in operating profit to Rs 1,514.40 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 34.08% to 35.30%. Purchase of finished goods cost fell from 1.84% to 1.57%. Employee cost decreased from 23.25% to 20.49%. Other expenses rose from 18.09% to 23.39%. Preoperation capitalised expenses fell from 5.05% to 4.96%.

Other income rose 51.99% to Rs 221 crore. PBIDT rose 13.89% to Rs 1735.4 crore. Provision for interest rose 198.07% to Rs 170.2 crore.

PBDT rose 6.72% to Rs 1565.2 crore. Provision for depreciation rose 24.49% to Rs 749.4 crore.

Profit before tax down 5.64% to Rs 815.80 crore. Share of profit/loss was 17.54% higher at Rs -126.9 crore. Extraordinary items were decreased to Rs -288.40 crore. Provision for tax was expense of Rs 172 crore, compared to Rs 152.9 crore. Effective tax rate was 42.95% compared to 23.87%.

Minority interest increased 1.41% to Rs 79.00 crore. Net profit attributable to owners of the company decreased 63.52% to Rs 149.50 crore.

Promoters’ stake was 60.64% as of 31 December 2022 ,compared to 60.64% as of 31 December 2021 .

Full year results analysis.

Net sales (including other operating income) of Biocon has increased 14.57% to Rs 8184 crore. Sales of Novel Biologics segment has gone up 385.71% to Rs 51.00 crore (accounting for 0.60% of total sales). Sales of Research service segment has gone up 19.22% to Rs 2,604.20 crore (accounting for 30.78% of total sales). Sales of Generics segment has gone down 0.92% to Rs 2,340.90 crore (accounting for 27.67% of total sales). Sales of Biosimilars segment has gone up 23.72% to Rs 3,464.30 crore (accounting for 40.95% of total sales). Inter-segment sales rose Rs 214.60 crore to Rs 276.40 crore.

Profit before interest, tax and other unallocable items (PBIT) has jumped 2.75% to Rs 1,099.90 crore. PBIT of Novel Biologics segment fell 977.45% to Rs -219.80 crore (accounting for -19.98% of total PBIT). PBIT of Research service segment rose 18.63% to Rs 515.10 crore (accounting for 46.83% of total PBIT). PBIT of Generics segment fell 10.33% to Rs 261.40 crore (accounting for 23.77% of total PBIT). PBIT of Biosimilars segment rose 48.74% to Rs 543.20 crore (accounting for 49.39% of total PBIT).

PBIT margin of Novel Biologics segment fell from negative 194.29% to negative 430.98%. PBIT margin of Research service segment fell from 19.88% to 19.78%. PBIT margin of Generics segment fell from 12.34% to 11.17%. PBIT margin of Biosimilars segment rose from 13.04% to 15.68%. Overall PBIT margin fell from 14.55% to 13.00%.

Operating profit margin has jumped from 23.14% to 24.07%, leading to 19.20% rise in operating profit to Rs 1,970.20 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 32.69% to 33.34%. Purchase of finished goods cost rose from 1.39% to 1.91%. Employee cost decreased from 23.42% to 22.27%. Other expenses fell from 20.26% to 19.14%. Preoperation capitalised expenses rose from 4.72% to 5.64%.

Other income fell 16.42% to Rs 212.7 crore. PBIDT rose 14.45% to Rs 2182.9 crore. Provision for interest rose 17.16% to Rs 67.6 crore. Loan funds rose to Rs 5,146.60 crore as of 31 March 2022 from Rs 4,481.10 crore as of 31 March 2021. Inventories rose to Rs 2,298.20 crore as of 31 March 2022 from Rs 1,866.60 crore as of 31 March 2021. Sundry debtors were higher at Rs 2,058.20 crore as of 31 March 2022 compared to Rs 1,503.30 crore as of 31 March 2021. Cash and bank balance declined from Rs 2,015.40 crore as of 31 March 2021 to Rs 1,747.50 crore as of 31 March 2022. Investments declined from Rs 1,951.90 crore as of 31 March 2021 to Rs 1,587.90 crore as of 31 March 2022.

PBDT rose 14.37% to Rs 2115.3 crore. Provision for depreciation rose 13.86% to Rs 814.2 crore. Fixed assets increased to Rs 10,653.00 crore as of 31 March 2022 from Rs 9,137.70 crore as of 31 March 2021. Intangible assets stood at Rs 26.40 crore.

Profit before tax grew 14.68% to Rs 1,301.10 crore. Share of profit/loss was 160.58% lower at Rs -206.9 crore. Provision for tax was expense of Rs 211.5 crore, compared to Rs 221.5 crore. Effective tax rate was 21.51% compared to 20.75%.

Minority interest increased 16.56% to Rs 123.20 crore. Net profit attributable to owners of the company decreased 12.44% to Rs 648.40 crore.

Equity capital increased from Rs 600.00 crore as of 31 March 2021 to Rs 600.30 crore as of 31 March 2022. Per share face Value remained same at Rs 5.00.

Promoters’ stake was 60.64% as of 31 March 2022 ,compared to 60.67% as of 31 March 2021 .

Cash flow from operating activities increased to Rs 1,176.60 crore for year ended March 2022 from Rs 1,159.70 crore for year ended March 2021. Cash flow used in acquiring fixed assets during the year ended March 2022 stood at Rs 1,924.80 crore, compared to Rs 1,746.30 crore during the year ended March 2021.

Other Highlights

In Q3 FY23, Generics business went up 18% compared to Q3 FY22. Biosimilars segment went up 54% and Research services up 23% on YoY basis.

In Q3 FY23, Generics business contributed 24% of total revenue, Biosimilars 50% and Research services 26%.

Biocon had raised USD 420 million of mezzanine financing to part finance the USD 650 million equity infusion into Biocon Biologics. Biocon has entered into a definitive agreement with Kotak Strategic Situations Fund for a structured funding upto Rs 1200 crore. This funding together with recently concluded stake sale in Syngene will help reduce net debt.

Management Comments :
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics said, “Q3 FY23 has been an eventful quarter which saw the completion of the global acquisition of our partnered Biosimilars business from Viatris on Nov 29, 2022. We are now implementing country-wise integration of the business to maximize the value of the combined entity to propel growth. Biosimilars as a business segment offers differentiated growth to Biocon Biologics based on vertical integration and a unique portfolio of Insulins and antibody based immunotherapeutics. This quarter captures a fraction of the acquired business, but from Q4FY23 onwards, the financials will recognise the entire Biosimilars business. “Biocon’s consolidated revenues for the quarter grew 36% to Rs 3,020 crore on the back of robust performance across all its three businesses. The biggest contribution came from the Biosimilars business, which reported a 54% increase in revenues to Rs 1,507 crore. Research Services revenues at Rs 786 crore and Generics business revenues at Rs 718 crore, grew 23% and 18%, respectively. The advancement of our research pipeline led to Rs 337 crore Net R&D investments this quarter, which will drive Biocon’s future growth. We reported a strong EBITDA growth of 35% to Rs 723 crore, representing a healthy EBITDA margin of 24%. Core EBITDA grew 49% to Rs 1,069 crore. As a part of our strategy to reduce the acquisition debt, Biocon has raised funds through a partial divestment of its stake in Syngene. “We expect to end FY23 on a strong note with healthy growth across businesses. Biocon Biologics is tracking towards exiting the year at a USD 1 billion trajectory, excluding vaccines.”

Siddharth Mittal, CEO & Managing Director, Biocon said, “The Generics business’ third-quarter results were in line with our expectations, delivering healthy sequential and year-on-year revenue growth. The performance was driven by immunosuppressant API sales and Generic Formulations, which saw an uptick in the sales of statins as well as recent product launches. Margins, compared to the previous year, were muted by the product mix and continuing pricing pressure in the U.S. market. “Our geographical expansion continued to gain traction with the signing of a partnership agreement with Zentiva for commercializing Liraglutide in Europe, as well as a long-term strategic partnership with Farmanguinhos in Brazil for the supply and tech-transfer of a finished dose formulation immunosuppressant product. These partnerships will contribute towards attaining mid-teens growth in the short to medium term. We also secured approvals for some of our key formulation products inEurope. Our focus remains on geographical expansion, new product launches, strengthening our product pipeline and executing on key capex projects..”

Shreehas Tambe, CEO & Managing Director, Biocon Biologics said, “Biocon Biologics recorded its highest ever quarterly revenue of Rs 1,507 crore, reflecting a growth of 54% on the back of our acquisition of Viatris` biosimilars business and continued growth in BBL led markets. This strong performance has translated to an EBITDA growth of 53% to Rs 361 crore. This landmark acquisition marks an inflection point in our transformational journey and positions Biocon Biologics as a unique, fully integrated, leading global biosimilars enterprise. While our biosimilars portfolio continues to gain market share in the U.S. and EU, our business in the Emerging Markets is also on a growth trajectory with product launches in 8 new markets this quarter." “We have drawn up a comprehensive plan to integrate the acquired Viatris business into Biocon Biologics and migration of business operations is scheduled in a phased manner to ensure business continuity and uninterrupted service to customers and patients.”

Jonathan Hunt, CEO & Managing Director, Syngene said, “We continue to see good demand in the main client markets of U.S. and Europe which - combined with strong execution and forward planning - has helped us deliver solid revenue growth in the third quarter. We are pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres, was solid. In Development Services, repeat orders from existing clients, as well as an increase in the number of collaborations with emerging biopharma companies drove a robust performance. In Manufacturing, the highlight of the quarter was the successful inspection of our biologics facilities by the U.S. FDA, EMA and MHRA. Based on our strong performance to date, we are confident of meeting the upgraded annual revenue growth guidance of high teens.”

Biocon : Consolidated Results

	Quarter ended			Year to Date			Year ended
Particulars	202212	202112	Var.(%)	202212	202112	Var.(%)	202203	202103	Var.(%)
Net Sales (including other operating income)	2,941.10	2,174.20	35.27	7,400.30	5,775.20	28.14	8,184.00	7,143.10	14.57
OPM (%)	21.91	22.45	-55 bps	20.46	23.87	-340 bps	24.07	23.14	94 bps
OP	644.30	488.20	31.97	1,514.40	1,378.30	9.87	1,970.20	1,652.80	19.20
Other Inc.	78.60	48.30	62.73	221.00	145.40	51.99	212.70	254.50	-16.42
PBIDT	722.90	536.50	34.74	1,735.40	1,523.70	13.89	2,182.90	1,907.30	14.45
Interest	120.30	14.70	718.37	170.20	57.10	198.07	67.60	57.70	17.16
PBDT	602.60	521.80	15.48	1,565.20	1,466.60	6.72	2,115.30	1,849.60	14.37
Depreciation	301.1	205.7	46.38	749.4	602	24.49	814.2	715.1	13.86
PBT	301.50	316.10	-4.62	815.8	864.6	-5.64	1301.1	1134.5	14.68
Share of Profit/(Loss) from Associates	-55.6	-47.2	-17.80	-126.9	-153.9	17.54	-206.9	-79.4	-160.58
PBT before EO	245.9	268.9	-8.55	688.9	710.7	-3.07	1094.2	1055.1	3.71
EO Income	-271.4	0	-	-288.4	-70.1	-311.41	-111.1	12.6	PL
PBT after EO	-25.5	268.9	PL	400.5	640.6	-37.48	983.1	1067.7	-7.92
Taxation	-4.8	49.3	LP	172	152.9	12.49	211.5	221.5	-4.51
PAT	-20.7	219.6	PL	228.5	487.7	-53.15	771.6	846.2	-8.82
Minority Interest (MI)	21.1	32.5	-35.08	79	77.9	1.41	123.2	105.7	16.56
Net profit	-41.8	187.1	PL	149.5	409.8	-63.52	648.4	740.5	-12.44
P/(L) from discontinued operations net of tax	0	0	-	0	0	-	0	0	-
Net profit after discontinued operations	-41.8	187.1	PL	149.5	409.8	-63.52	648.4	740.5	-12.44
EPS (Rs)*	0.53	1.56	-66.00	2.50	3.83	-34.58	6.07	6.09	-0.44

* EPS is on current equity of Rs 600.30 crore, Face value of Rs 5, Excluding extraordinary items.
# EPS is not annualised
bps : Basis points
EO : Extraordinary items
Figures in Rs crore
Source: Capitaline Corporate Database

Biocon : Consolidated Segment Results

	Quarter ended				Year to Date				Year ended
	% of (Total)	202212	202112	Var.(%)	% of (Total)	202212	202112	Var.(%)	% of (Total)	202203	202103	Var.(%)
Sales
Enzymes	0.00	0.00	0.00	-
Pharma	0.00	0.00	0.00	-
Novel Biologics	0.00	0.00	15.60	-	0.60	51.00	10.50	385.71
Research service	26.11	785.90	641.40	22.53	28.93	2,198.50	1,846.10	19.09	30.78	2,604.20	2,184.30	19.22
Generics	23.84	717.60	607.40	18.14	25.27	1,920.10	1,623.70	18.25	27.67	2,340.90	2,362.70	-0.92
	50.05	1,506.60	981.40	53.52	45.80	3,480.60	2,482.00	40.23	40.95	3,464.30	2,800.20	23.72
Total Reported Sales	100.00	3,010.10	2,245.80	34.03	100.00	7,599.20	5,990.50	26.85	100.00	8,460.40	7,357.70	14.99
Less: Inter segment revenues		69.00	71.60	-3.63		198.90	215.30	-7.62		276.40	214.60	28.80
Net Sales	100.00	2,941.10	2,174.20	35.27	100.00	7,400.30	5,775.20	28.14	100.00	8,184.00	7,143.10	14.57
PBIT
Enzymes	0.00	0.00	0.00	-
Pharma	0.00	0.00	0.00	-
Novel Biologics	-13.52	-37.40	-49.20	23.98	-9.43	-69.20	-169.10	59.08	-19.98	-219.80	-20.40	-977.45
Research service	50.56	139.90	128.40	8.96	49.43	362.80	336.00	7.98	46.83	515.10	434.20	18.63
Generics	26.06	72.10	66.60	8.26	25.83	189.60	145.70	30.13	23.77	261.40	291.50	-10.33
	36.90	102.10	123.80	-17.53	34.16	250.70	398.90	-37.15	49.39	543.20	365.20	48.74
Total PBIT	100.00	276.70	269.60	2.63	100.00	733.90	711.50	3.15	100.00	1,099.90	1,070.50	2.75
Less : Interest		0.00	0.00	-		0.00	0.00	-		0.00	0.00	-
Add: Other un-allcoable		-30.80	-0.70	-4,300.00		-45.00	-0.80	-5,525.00		-5.70	-15.40	62.99
PBIT Margin(%)
Enzymes		0.00	0.00	0.00
Pharma		0.00	0.00	0.00
Novel Biologics		0.00	-315.38	31,538.46		0.00	-436.95	43,695.09		-430.98	-194.29	-23,669.47
Research service		17.80	20.02	-221.75		16.50	18.20	-169.84		19.78	19.88	-9.86
Generics		10.05	10.96	-91.74		9.87	8.97	90.12		11.17	12.34	-117.09
		6.78	12.61	-583.78		7.20	16.07	-886.89		15.68	13.04	263.80
PBT	100.00	245.90	268.90	-8.55	100.00	688.90	710.70	-3.07	100.00	1,094.20	1,055.10	3.71

Previous News

Stock Alert: Force Motors, Biocon, Adani Wilmar, JSW Energy, GE Vernova, ONGC,
( Market Commentary - Stock Alert 05-Mar-25 08:36 )

Biocon rises after biosimilars arm gets regulatory approval from Japan Health Authority for Ustekinumab
( Hot Pursuit - 07-Jan-25 09:36 )

Biocon's Ustekinumab biosimilar gets marketing authorisation for EU region
( Hot Pursuit - 18-Feb-25 09:30 )

Biocon Ltd spurts 1.41%, up for third straight session
( Hot Pursuit - 15-Oct-24 13:05 )

Biocon Biologics launches YESINTEK™
( Corporate News - 24-Feb-25 19:17 )

Board of Biocon recommends final dividend
( Corporate News - 16-May-24 17:54 )

Biocon Ltd soars 1.22%, rises for fifth straight session
( Hot Pursuit - 27-Mar-24 13:00 )

Biocon announces board meeting date
( Corporate News - 04-Oct-24 09:29 )

Biocon Ltd up for five straight sessions
( Hot Pursuit - 19-Feb-24 13:00 )

Biocon Biologics completes final remittance under acquisition agreement with Viatris
( Corporate News - 30-Dec-24 10:10 )

Biocon arm gets USFDA nod for chronic heart failure drug
( Hot Pursuit - 02-Sep-24 08:59 )